FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: U.S. POINTER STUDY SHOWS STRUCTURED LIFESTYLE PROGRAM TARGETING MULTIPLE RISK FACTORS IMPROVES COGNITION IN OLDER ADULTS AT RISK OF COGNITIVE DECLINE
Two lifestyle interventions in U.S. POINTER improved cognition in older adults at risk of cognitive decline. A structured intervention with more support and accountability showed greater improvement compared to a self-guided intervention.
In a large, representative group of older adults at high risk for cognitive decline, multidomain lifestyle interventions were delivered with high adherence and safety.
Cognitive benefits were consistent across age, sex, ethnicity, heart health status and apolipoprotein E-e4 genotype.
TORONTO, July 28, 2025 /CNW/ -- The Alzheimer's Association U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) — a two-year, multi-site clinical trial testing two different lifestyle interventions in a representative population of older adults at risk for cognitive decline and dementia — found that both interventions improved cognition in older adults at risk of cognitive decline. Trial participants in the structured (STR) intervention showed greater improvement on global cognition compared to the self-guided (SG) intervention, protecting cognition from normal age-related decline for up to two years. The STR intervention differed from the SG intervention in intensity, structure, accountability and support provided.
The results were reported for the first time today at the Alzheimer's Association International Conference (AAIC) 2025 in Toronto and online. "Effects Of Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The U.S. POINTER Randomized Clinical Trial," was published in The Journal of the American Medical Association (JAMA) simultaneously with the report at AAIC 2025.
U.S. POINTER is the first large-scale, randomized controlled clinical trial to demonstrate that an accessible and sustainable healthy lifestyle intervention can protect cognitive function in diverse populations in communities across the United States.
"As the burden of dementia grows world-wide, U.S. POINTER affirms a vital public health message: healthy behavior has a powerful impact on brain health," said Joanne Pike, DrPH, Alzheimer's Association president and CEO.
"This is a critical public health opportunity. The intervention was effective across a broad, representative group — regardless of sex, ethnicity, APOE genetic risk, or heart health status — demonstrating its applicability and scalability for communities across the country," said Pike. "The positive results of U.S. POINTER encourage us to look at the potential for a combination of a lifestyle program and drug treatment as the next frontier in our fight against cognitive decline and possibly dementia."
U.S. POINTER leadership acknowledges participants, their family members and study site staff for their unique and essential contributions: "You helped change what we know about brain health. Thanks to your dedication, time and support, U.S. POINTER delivered groundbreaking results. Your children, grandchildren and generations to come will benefit from the commitment you made."
Both interventions focused on physical exercise, nutrition, cognitive challenge and social engagement, and heart health monitoring, but differed in intensity, structure, accountability and support provided.
Structured lifestyle intervention. Participants attended 38 facilitated peer team meetings over two years, and were provided with a prescribed activity program with measurable goals for: aerobic, resistance and stretching exercise; adherence to the MIND diet; cognitive challenge through BrainHQ training and other intellectual and social activities; and regular review of health metrics and goal-setting with a study clinician.
Self-guided lifestyle intervention. Participants attended six peer team meetings to encourage self-selected lifestyle changes that best fit their needs and schedules. Study staff provided general encouragement without goal-directed coaching.
"The potential to improve cognition with fewer resources and lower participant burden is compelling. It highlights that while not everyone has the same access or ability to adhere to more intensive behavior interventions, even modest changes may protect the brain," said Laura D. Baker, Ph.D., Professor of Gerontology and Geriatrics, and Internal Medicine, at Wake Forest University School of Medicine and Advocate Health, and U.S. POINTER principal investigator.
"These are the initial results. Over the coming weeks and months, study leadership will be exploring all of the data collected in the trial to paint an even more comprehensive picture of the U.S. POINTER intervention effects on brain health," Baker said.
People with cognitive decline and dementia often have a variety of damaging changes in their brain. This means effective treatment will likely require a multi-pronged or combination strategy to address multiple disease mechanisms.
"Complex diseases like heart disease and cancer use combination treatment strategies tailored to individual characteristics. The next generation of treatments for diseases like Alzheimer's will likely integrate drug and non-drug strategies. U.S. POINTER provides a strong foundation for such combination approaches," said Heather M. Snyder, Ph.D., Alzheimer's Association study primary investigator and senior vice president of medical and scientific relations.
"While these results are fascinating and extremely hopeful, how they are rolled out to the public — especially those at risk for Alzheimer's and other diseases that cause dementia — needs to be handled with care and individual attention to tailor to the local environment," said Snyder.
The Alzheimer's Association has invested nearly $50 million to lead this study to date, with additional support from the National Institute on Aging at the National Institutes of Health for add-on studies exploring imaging, vascular measures, sleep and gut microbiome-related health data. In addition to its investments to date, the Alzheimer's Association will invest more than $40 million over the next four years to continue to follow U.S. POINTER participants, and to bring U.S. POINTER interventions to communities across America.
U.S. POINTER is a phase 3, five-site, two-year, single-blind randomized clinical trial of two lifestyle interventions in older adults at risk for dementia. U.S. POINTER was developed to assess whether the results of the FINGER study [ Lancet, 6-6-15] generalize to a larger, more diverse U.S. population at risk for cognitive decline and dementia, using culturally adapted protocols. The primary aim was to compare the effects of two multimodal lifestyle interventions on global cognitive function in 2,000+ at-risk older adults. Secondary aims assessed intervention effects on specific cognitive domains, and potential differences based on baseline cognition, sex, age, APOE-e4 genotype, and cardiovascular risk.
The study was conducted at five geographically dispersed U.S. academic centers and health care systems in partnership with the Alzheimer's Association. Participant eligibility criteria were designed to enrich the risk of cognitive decline and included older age (60-79 years), sedentary lifestyle, suboptimal diet and cardiometabolic health, and family history of memory impairment. 2,111 participants were enrolled and randomized to STR (n=1,056) or SG (n=1,055). Mean age was 68.2 years, 68.9% were female, 30.8% were from ethnoracial minority groups. Seventy-eight percent (78%) reported a first-degree family history of memory loss, and 30% were APOE-e4 carriers. Retention was high, with 89% completing the final 2 year assessment.
At two years, there was a statistically significant intervention group difference on the primary outcome. Global cognitive composite scores (primary outcome) increased over time in both groups but the improvement over time was statistically significant for a greater benefit for the STR versus SG: 0.029 SD per year (95% CI, 0.008-0.050, P =0.008). For secondary outcomes, the increase in executive function z-score was greater in STR than SG by 0.037 SD per year (95% CI, 0.010-0.064). Processing speed showed a similar trend but was not statistically significant. There were no group differences in memory.
Looking ahead, the Association will build on the momentum of U.S. POINTER by launching several programs and initiatives, including:
A personal brain health assessment tool.
A virtual brain health training program for health care providers.
A community recognition program for organizations championing brain health.
A brain health roundtable that will unite leaders across health care, public health, community and corporate sectors to accelerate impact.
About AAIC
AAIC is the world's largest gathering of researchers from around the world focused on Alzheimer's and other diseases that cause dementia. As a part of the Alzheimer's Association's research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community.
AAIC 2025: alz.org/aaic
AAIC 2025 newsroom: alz.org/aaic/pressroom.asp
AAIC 2025 hashtag: #AAIC25
About the Alzheimer's Association
The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call +1 800.272.3900.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
South Carolina parents call for safety warnings after son killed by brain-eating amoeba in lake
Two weeks after Jaysen Carr spent the Fourth of July swimming and riding on a boat on one of South Carolina's most popular lakes, he was dead from an amoeba that lives in the warm water and entered his brain through his nose. His parents had no clue the brain-eating amoeba, whose scientific name is Naegleria fowleri, even existed in Lake Murray, just 15 miles (24 kilometres) west of Columbia. They found out when a doctor, in tears, told them the diagnosis after what seemed like a fairly regular headache and nausea took a serious turn. Jaysen, 12, fought for a week before dying on July 18, making him one of about 160 people known to have died from the amoeba in the U.S. in the past 60 years. As they grieve their son, the boy's parents said they were stunned to learn South Carolina, like most other U.S. states, has no law requiring public reporting of deaths or infections from the amoeba. The lake wasn't closed and no water testing was performed. If they hadn't spoken up, they wonder if anyone would have even known what happened. 'I can't believe we don't have our son. The result of him being a child was losing his life. That does not sit well. And I am terrified it will happen to someone else,' Clarence Carr told The Associated Press as his wife sat beside him, hugging a stuffed tiger that had a recording of their middle child's heartbeat. What is the brain-eating amoeba that killed an American boy swimming in a lake? Jaysen loved sports. He played football and baseball. He loved people, too. As soon as he met you, he was your friend, his father said. He was smart enough to have skipped a grade in school and to play several instruments in his middle school band in Columbia. 'He either loved you or he just didn't know you,' his father said. 'He was the type of person who could go to a jump park and five minutes later say, 'This is my friend James.'' Friends invited Jaysen and his family for the Fourth of July holiday weekend on the lake, where Jaysen spent hours swimming, fishing and riding on an inner tube that was being pulled by a boat. 'Mom and Dad, that was the best Fourth of July I've ever had,' Clarence Carr remembered his son telling him. A few days later, Jaysen's head started to hurt. Pain relievers helped. But the next day the headache got worse and he started throwing up. He told the emergency room doctors exactly where he was hurting. But soon he started to get disoriented and lethargic. The amoeba was in his brain, already causing an infection and destroying brain tissue. It entered through his nose as water was forced deep into his nasal passages, possibly from one of the times Jaysen jumped into the water. It then travelled along his olfactory nerve into his brain. The amoeba caused an infection called primary amebic meningoencephalitis. Fewer than 10 people a year get it in the U.S., and over 95% of them die. The last death from the amoeba in South Carolina was in 2016, according to the Centers for Disease Control and Prevention. The amoeba is fairly common. There is no science-based threshold for what level of the organism in the water would be safe or unsafe, and it would be difficult to test water regularly, the South Carolina Department of Environmental Services said in a statement. Researchers are still trying to figure out why the infections are so rare. Some people have been found to have had antibodies, signalling they may have survived exposure. Others may die from brain swelling and other problems without the amoeba ever being detected. Last year, the CDC started a pilot program of giving infected patients an antibiotic approved for use in Europe that has killed the amoeba in lab studies The amoeba becomes dangerous in water that stays over 77 degrees Fahrenheit (25 degrees Celsius) and for years has been seen almost exclusively in the summer in the southern part of the country. But a few recent cases have popped up in Maryland, Indiana and Minnesota, scientists said. The CDC said 167 cases of the infection have been reported in the U.S. between 1962 and 2024, and only four people have survived. One infection in a body of water doesn't increase the chances of another infection in the same body of water, the CDC said. The amoeba cannot move from one person to another. Boys seem most susceptible, but researchers don't know if that is simply because they are more likely to jump and dive into the water or play in sediment at the bottom of lakes. The amoeba can show up in hot springs, rivers and, on rare occasions, in tap water. That's why doctors recommend using sterile water for cleaning nasal passages with a neti pot. The only way to be completely safe is to not swim in lakes or rivers and, if you do, keep your head above water. Pinching your nose or using nose clips when diving or swimming can keep water out of your nose. As he sat in an intensive care hospital room with his son, Clarence Carr couldn't help but think of all the people on the lake. He wondered if any of them had any clue about the microscopic danger in that water. 'There are entire families out there on pontoon boats, jumping off, just like our kids were having the time of their lives,' he said. 'It very well could be their last moments, and they are unaware of it.'
Cision Canada
2 hours ago
- Cision Canada
Staffy Health Becomes First in Canada to Launch Biometric Check-In and One-Device Policy for Healthcare Staffing
TORONTO, July 30, 2025 /CNW/ - Staffy Health, a leading on-demand healthcare staffing platform ( com), today announced the launch of biometric shift authentication and a one-device-per-worker policy, becoming the first healthcare staffing platform in Canada to implement both technologies. Biometric shift authentication uses secure facial or fingerprint recognition to verify a contractor's identity at check-in and check-out, creating a tamper-proof record of shift attendance. This ensures that every shift is accurately recorded and securely linked to the right professional. At the same time, the new one-device-per-worker policy limits shift check-ins to a single registered mobile device, preventing device sharing or account misuse. The biometric rollout is occurring in phases: Phase 1 (Completed): All new contractors register with biometric data upon onboarding. Phase 2 (Underway): Existing contractors are updating their profiles and registering biometric credentials. Phase 3 (September 2025): All shifts will require biometric check-in and check-out for completion. The One Device = One Check-In policy, now live across Canada, binds each shift to a single mobile device registered to the contractor's account. This additional layer of verification increases the reliability of clock-in data and simplifies compliance audits. These combined updates support: Greater shift-level accuracy and cleaner invoicing Reduced identity fraud and unauthorized clock-ins Transparent audit trails aligned with regulatory and internal standards Real-time confirmation of on-site staff Together, these measures set a new benchmark for shift integrity and real-time visibility, giving healthcare facilities more control, cleaner records, and greater peace of mind. Staffy also announced the release of its new worker reliability rating, a feature that gives client partners additional transparency when booking shifts. Each contractor now has a live score based on their attendance, timeliness, and performance across previous shifts. The goal is simple: to help organizations make informed staffing decisions with greater confidence. "No one asked us to implement these changes — we're doing it because it's the right thing to do," said Peter Faist, CEO of Staffy Health. "We're building tools that empower our partners to operate with clarity, security, and trust every step of the way." Unlike traditional agencies, Staffy uses technology to provide on-demand access to qualified healthcare professionals while giving administrators real-time visibility, digital records, and customizable controls. These updates reflect the company's continued investment in providing a transparent, modern alternative to conventional staffing solutions. **About Staffy Health** Staffy Health is a Canadian-owned digital staffing platform transforming how healthcare organizations access qualified professionals. The company connects hospitals, long-term care homes, and homecare providers to vetted nurses, personal support workers, and allied health professionals through a secure, on-demand marketplace.
Cision Canada
3 hours ago
- Cision Canada
Rocket Science Health Secures U.S Patent for Precision Intranasal Drug Delivery Platform
Patent covers a method of targeted drug delivery to the brain and central nervous system via subregions of the intranasal cavity Builds on recent corporate milestones and sets the stage for future strategic partnerships Advances Rocket Science Health's progression towards broader clinical applications VICTORIA, BC, July 30, 2025 /CNW/ - Rocket Science Health Corp., a Canadian healthcare technology company focused on precision drug delivery for brain therapeutics and vaccines, today announced it has secured U.S. Patent No. 12,343,489 from the United States Patent and Trademark Office for its investigational precision intranasal drug delivery device. The patent covers a method of targeted delivery of therapeutic compositions to subregions of the intranasal cavity, including the olfactory, dispensed from a vantage point that is essential for maximizing on-target and avoiding off-target delivery of drugs. "Getting drugs to the brain is one of medicine's hardest problems and our proprietary technology is designed to address that challenge – not just for brain delivery, but also for vaccines and other treatments that need more targeted approaches. It's not rocket science, but a simple drug delivery device that has the potential to make sophisticated drugs work, while broadening access to live-saving treatments," said Sohier Hall, President of Rocket Science Health. "The granting of these key patents is an important milestone on our journey to scale and accelerate the delivery of next-generation brain and central nervous system treatments, with the goal of initiating human clinical trials with our device in the near future." The upper nasal cavity offers a unique access point to the brain and central nervous system that can optimize the brain's exposure to drug therapies, accelerate the onset of action, reduce drug doses, improve the accuracy of delivery, and potentially improve health outcomes for millions of patients. However, commercially available nasal spray devices can only deliver a fraction of their dose volume to the olfactory region due to the anatomical characteristics of the nasal cavity. At the same time, nearly all small and large molecule drug therapies approved by the FDA cannot enter the central nervous system when taken through other, traditional routes of administration. Initial peer-reviewed research and in-human imaging studies have validated Rocket Science Health's patented technology and demonstrated precise, repeatable drug deposition to subregions of the intranasal cavity. This technology is compatible with delicate drug formulations, including lipid nanoparticles (LNPs), biologics, peptides, and can handle a range of viscosities. The Company is evaluating licensing of its technology to developers where precision delivery is a potential factor for success in their pending clinical trial. The intellectual property applies to both next-generation therapies or reestablishing existing molecules with greater effect and patent ability. With strong intellectual property, validated in-human results, and industry-leading execution partners in place, Rocket Science is well-positioned to advance toward broader clinical applications in brain-targeted drug delivery. For more information on Rocket Science Health, visit About Rocket Science Health: Rocket Science Health, founded by Canadian business leader Kenneth Irving, develops precision drug delivery technologies focused on brain-targeted therapeutics and vaccines. Our needle-free intranasal device enables non-clinical self-administration for at-home care, emergency rescue, and mass immunization. Its fluidics are specifically engineered for today's delicate biologics and dose-dependent drugs. As a team, we are driven to create innovations that expand access to care—especially for under-resourced communities and for individuals who face physical, cognitive, or challenging care environments where thoughtful design can improve health outcomes.
